Cell and gene therapy occupies a unique position in the life sciences landscape: the science is transformative, the regulatory pathway is among the most complex in medicine, and the capital requirements are enormous. Companies in this sector are simultaneously managing IND filings, CMC regulatory submissions, manufacturing compliance documentation, clinical trial administration, and intensive investor communication — all while racing to generate the clinical evidence that justifies continued investment. In 2026, CGT companies are increasingly deploying virtual assistants to manage the administrative and coordination burden that those parallel demands create.
The Regulatory Documentation Challenge in CGT
Cell and gene therapy regulatory submissions are exceptionally document-intensive. CMC sections for CGT products involve detailed manufacturing process descriptions, raw material qualification documentation, analytical method validation summaries, and comparability study reports that generate substantial file management requirements. For companies operating under FDA Regenerative Medicine Advanced Therapy (RMAT) designation or EMA PRIority MEdicines (PRIME) designation, accelerated review timelines add additional coordination complexity.
Virtual assistants with regulatory affairs experience are supporting CGT regulatory teams in several specific ways: maintaining the master regulatory correspondence file, tracking FDA Type A, B, and C meeting request timelines and follow-up requirements, coordinating document package assembly for IND amendments and BLA preparation, and managing the version control systems that track document evolution across multiple regulatory submissions.
"The sheer volume of correspondence between our regulatory team and the FDA, combined with our CMC manufacturing partners' documentation cycles, was creating a tracking nightmare," said Dr. Angela Morrison, VP of Regulatory Affairs at a Boston-based AAV gene therapy company. "We brought on two VAs with regulatory documentation backgrounds, and our submission preparation cycle time dropped by about three weeks."
A 2025 survey by the American Society of Gene and Cell Therapy found that regulatory documentation management consumed an average of 31 percent of regulatory affairs staff hours at CGT companies with active IND programs — among the highest administrative burden percentages of any life sciences subsector.
Manufacturing Regulatory Coordination: A Distinct Challenge
CGT companies typically rely on a combination of in-house and contract manufacturing organizations for their cell or vector manufacturing processes. Coordinating the regulatory documentation requirements between internal regulatory affairs teams and external CMO partners — including batch record review coordination, deviation notification tracking, and regulatory agency inspection preparation — requires sustained administrative infrastructure.
VAs in manufacturing regulatory coordination roles maintain communication trackers between regulatory and manufacturing teams, manage the distribution of regulatory agency communications to affected manufacturing stakeholders, and coordinate the assembly of CMC regulatory responses that involve contributions from multiple internal and external subject matter experts.
The Alliance for Regenerative Medicine's 2025 operational benchmarking report found that CGT companies with structured administrative support for CMO regulatory coordination reported 40 percent fewer documentation cycle delays — defined as missing an internal document submission deadline due to coordination failures rather than technical issues.
Investor Coordination in a Capital-Intensive Sector
Cell and gene therapy companies are among the most capital-intensive businesses in life sciences, with Phase I/II clinical programs regularly requiring $100 million to $300 million in development capital before pivotal study initiation. Managing the investor relations function at that scale — with syndicates that may include twenty to forty institutional investors plus strategic partners — is a full-time coordination responsibility that few companies staff adequately.
Virtual assistants supporting CGT investor relations functions are managing investor data room maintenance and access permissions, coordinating the preparation of quarterly scientific and operational updates, scheduling investor days and scientific advisory board presentations, and maintaining the investor relationship database with accurate contact information and communication history.
According to PitchBook's 2026 Cell and Gene Therapy Investment Landscape Report, CGT companies that maintained consistent, structured quarterly communication with all investors in their syndicate raised subsequent rounds at 18 percent higher pre-money valuations on average than those with irregular investor communication practices, after controlling for clinical stage and indication.
James Callahan, a managing director at a life sciences-focused crossover fund in San Francisco, noted: "In CGT, the distance between clinical catalysts can be measured in years. The companies that maintain investor confidence during those intervals are the ones that communicate systematically — and that requires someone whose job is to manage that communication infrastructure."
Building Sustainable Operations in CGT
The CGT companies best positioned to manage their administrative complexity are those that have invested early in process documentation — creating the SOPs and communication templates that allow VAs to operate within well-defined parameters while maintaining the compliance discipline that highly regulated manufacturing and regulatory environments demand.
CGT companies exploring VA partnerships for regulatory administration and investor coordination can work with life sciences-specialized providers like Stealth Agents, which offers virtual assistants with the regulatory and operational experience needed to support complex development-stage life sciences companies.
As the CGT sector moves from its current early-commercial phase toward broader patient access, the companies with the most scalable administrative infrastructure will be best positioned to manage the regulatory and investor demands of that transition.
Sources
- American Society of Gene and Cell Therapy, Regulatory Affairs Staff Survey, 2025
- Alliance for Regenerative Medicine, Operational Benchmarking Report, 2025
- PitchBook, Cell and Gene Therapy Investment Landscape Report, Q1 2026